TurboCHO™ High Throughput Platform
From Gene Synthesis to Delivery as Fast as 5 Business Days
Receive your quote directly from the manufacturer.
High throughput (HT) gene to antibody production offers the most cost-effective option for small-scale recombinant antibodies. Empowered by GenScript’s high throughput gene synthesis platform and proprietary TurboCHO™ transient expression technology, small-scale projects, starting from customer-supplied sequences to purified products, can be completed in as short as 5 business days, helping to accelerate therapeutic development and commercialization globally!
Key features:
1. As fast as 5 business days
2. A large capacity of 1,000+ targets/day
3. Multiple isotypes, IgGs, Fab, scFv, VHH, bi-specific antibodies, and more
4. Flexible quantities (i.e., from ug to mg)
Relevant applications:
High throughput screening at the early stage of antibody drug discovery
Enhance productivity and purity in next-generation bispecific antibody manufacturing
Monday, July 14, at 15:00 BST | 16:00 CEST | 10:00 EDT | 7:00 PDT
Bispecific antibodies (BsAbs) are at the forefront of next-generation antibody therapies, offering immense potential but also presenting significant production challenges, such as secretion inefficiencies, chain mispairing, and impurity formation.
Join Dr. Heng Tai Liew, Senior Protein Scientist at GenScript Biotech and discover how GenScript's TurboCHO™ technology overcomes these hurdles through an integrated and iterative workflow that optimizes cell lines, vectors, and media using Design of Experiments (DOE) to refine chain ratios and boost yields. This approach is complemented by a both streamlined and customized purification strategy that utilizes advanced chromatography techniques, enabling selective impurity removal based on molecular differences to achieve superior purity.
Real-world case studies validate the efficacy of this systematic method, demonstrating its capacity to resolve common BsAb production obstacles and support a range of formats from early-stage development through to clinical-scale manufacturing.
Key learning objectives:
- Characterize the key challenges in BsAb production, including issues related to secretion efficiency, chain mispairing, and impurity accumulation, and their impact on the scalability and therapeutic potential of next-generation antibody-based therapies.
- Learn how GenScript’s TurboCHO technology optimizes the production process, including the use of DOE-driven cycles to refine cell lines, vectors, media, and chain ratios for improved yields.
- Understand how GenScript leverages chromatography techniques to achieve high-purity bispecific antibodies and effectively address common production challenges from development to clinical application.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
